Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jun 14, 2026

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

Decrease in CD4+ T-cell counts in patients with multiple myeloma treated with bortezomib.

Ulrike Heider1, Jessica Rademacher, Martin Kaiser

  • 1Department of Hematology and Oncology, Charité-Universitätsmedizin Berlin, Germany.

Clinical Lymphoma, Myeloma & Leukemia
|April 8, 2010
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The frequent exacerbator phenotype in bronchiectasis revisited: Data from EMBARC registry.

American journal of respiratory and critical care medicine·2026
Same author

Teclistamab in relapsed/refractory light chain amyloidosis: A retrospective multicenter study by the German Society for Amyloid Diseases.

HemaSphere·2026
Same author

Clinical characteristics, risk factors, and outcome of Enterococcal bacteraemia: Assessment of the DENOVA score in a diverse patient cohort.

Infection·2026
Same author

Clinical and immunological effects of adding cyclophosphamide to pomalidomide-dexamethasone in relapsed-refractory multiple myeloma: The randomized MUKseven trial.

British journal of haematology·2026
Same author

Diagnostic discordance and differential diagnoses of community-acquired pneumonia in the emergency department.

BMC emergency medicine·2026
Same author

Erratum: Peripheral Measurable Residual Disease Activity Assessment by MALDI-TOF Mass Spectrometry in Patients With Newly Diagnosed Multiple Myeloma in the Phase III GMMG-HD7 Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same journal

Results of Third-Line Therapy in Philadelphia Chromosome-Positive Adult Acute Lymphoblastic Leukemia.

Clinical lymphoma, myeloma & leukemia·2026
Same journal

Potential Benefits and Harms of Screening Strategies for Monoclonal Gammopathy of Undetermined Significance in the US: A Simulation Study.

Clinical lymphoma, myeloma & leukemia·2026
Same journal

Impact of Treatment Sequencing With CAR T-cell Therapies and Bispecific Antibodies on Long-term Survival in 4L+ RRMM in the United States: A Simulation Model.

Clinical lymphoma, myeloma & leukemia·2026
Same journal

A Phase I Study of Copanlisib and Venetoclax in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma.

Clinical lymphoma, myeloma & leukemia·2026
Same journal

Autoimmune Features in Myelodysplastic Syndromes: Clinical and Molecular Heterogeneity With Integrated IPSS-M Analysis.

Clinical lymphoma, myeloma & leukemia·2026
Same journal

SOHO State of the Art Updates and Next Questions | Progress in Clonal Hematopoiesis of Indeterminate Potential/Clonal Cytopenia of Uncertain Significance.

Clinical lymphoma, myeloma & leukemia·2026
See all related articles

Bortezomib treatment for multiple myeloma significantly decreases CD4+ T cells, increasing VZV infection risk. Antiviral prophylaxis with acyclovir effectively prevents herpes zoster reactivation in these patients.

Area of Science:

  • Immunology
  • Oncology
  • Virology

Background:

  • Bortezomib is a key treatment for multiple myeloma.
  • Increased varicella zoster virus (VZV) reactivation is a concern in patients on bortezomib.
  • Understanding the impact of bortezomib on immune cells is crucial.

Purpose of the Study:

  • To investigate bortezomib's effect on T-cell subpopulations in multiple myeloma patients.
  • To assess the incidence of VZV reactivation during bortezomib therapy.
  • To evaluate the efficacy of acyclovir prophylaxis against VZV reactivation.

Main Methods:

  • Studied 53 multiple myeloma patients before and during bortezomib treatment.
  • Monitored CD4+ T-cell counts and incidence of VZV reactivation.
  • Compared VZV reactivation rates between patients receiving and not receiving acyclovir prophylaxis.

More Related Videos

Modeling Chemotherapy Resistant Leukemia In Vitro
08:41

Modeling Chemotherapy Resistant Leukemia In Vitro

Published on: February 9, 2016

Related Experiment Videos

Last Updated: Jun 14, 2026

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

Modeling Chemotherapy Resistant Leukemia In Vitro
08:41

Modeling Chemotherapy Resistant Leukemia In Vitro

Published on: February 9, 2016

Main Results:

  • Bortezomib treatment led to a significant decrease in CD4+ T cells in 77% of patients.
  • CD4+ T-cell counts dropped below 400/microL in 75% of patients during treatment.
  • Herpes zoster reactivation occurred in 8.8% of patients without acyclovir prophylaxis, versus 0% with prophylaxis.

Conclusions:

  • Bortezomib causes a transient reduction in CD4+ lymphocytes, elevating VZV infection risk.
  • Acyclovir prophylaxis is effective in preventing VZV reactivation in myeloma patients treated with bortezomib.
  • Reduced CD4+ T-cell counts are associated with herpes zoster occurrence.